Par, Reliant Settle ANDA Suit Over Generic Rythmol

Law360, New York (April 21, 2009, 12:00 AM EDT) -- Par Pharmaceutical Inc. and Reliant Pharmaceuticals Inc. have settled patent litigation over Par's efforts to make a generic version of the heart arrhythmia treatment Rythmol SR.

Under the agreement, Par will be able to introduce its generic product on Jan. 11, 2011, or earlier under certain circumstances, the company said Tuesday. All patent claims between the companies in the U.S. District Court for the District of Delaware have been dismissed.

Rythmol is an anti-arrhythmic agent, which suppresses fast rhythms of the heart. The patent covering the...
To view the full article, register now.